Steven Cohen’s Avalo Therapeutics AVTX Stock Holding History

Steven Cohen’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.1M	Buy	2,387,026 +1,470,884	+161%	+$23.3M	0.05%	478
2026 Q1	$13.7M	Buy	916,142 +288,640	+46%	+$4.51M	0.02%	1032
2025 Q4	$11.4M	Sell	627,502 -426,481	-40%	-$7.2M	0.01%	1278
2025 Q3	$13.4M	Buy	+1,053,983	New	+$9.06M	0.02%	689
2023 Q2	–	Sell	-4,586	Closed	-$1.93M	–	2171
2023 Q1	$1.93M	Buy	4,586 +2,500	+120%	+$1.97M	0.01%	986
2022 Q4	$2.52M	Hold	2,086	–	–	0.01%	894
2022 Q3	$1.66M	Hold	2,086	–	–	0.01%	962
2022 Q2	$3M	Hold	2,086	–	–	0.01%	838
2022 Q1	$4.36M	Hold	2,086	–	–	0.02%	738
2021 Q4	$10.2M	Hold	2,086	–	–	0.04%	505
2021 Q3	$13.1M	Buy	2,086 +1,633	+360%	+$13.2M	0.06%	424
2021 Q2	$4.27M	Sell	453 -398	-47%	-$3.33M	0.02%	631
2021 Q1	$7.4M	Buy	+851	New	+$8.04M	0.03%	497

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Steven Cohen's AVTX Position: Q2 2026 in Review

Steven Cohen increased its Avalo Therapeutics (AVTX) stake by 161% in Q2 2026, buying an estimated $23.3M and bringing the position to 2,387,026 shares worth $44.1M. The position accounts for 0.05% of the portfolio, ranked #478.

Steven Cohen first reported a position in AVTX in Q1 2021 and has held it in 13 quarters since. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Steven Cohen held 2,387,026 shares of Avalo Therapeutics worth $44.1M as of Q2 2026.
Steven Cohen bought 1,470,884 Avalo Therapeutics shares in Q2 2026, an estimated $23.3M.
Avalo Therapeutics made up 0.05% of Steven Cohen's portfolio in Q2 2026, its #478 holding.
Steven Cohen first reported a position in Avalo Therapeutics in Q1 2021 and has held it in 13 quarters since.
125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.